Dr. Javed Butler, former Chair of Medicine at UMMC, is having a record research year. While Butler is currently President of the Baylor Scott and White Research Institute and Senior Vice President for Baylor Scott and White Health, he has continued his academic affiliation with UMMC as Distinguished Professor of Medicine. Butler has authored >1000 publications, with 20+ in just the past few months. The EMPACT-MI trial, published last month in The New England Journal of Medicine, is one of Butler’s most important contributions to the field. This trial was named as a top 5 for the American College of Cardiology (ACC) 2024 annual meeting as part of the “Late-Breaking Clinical Trials sessions.” EMPACT-MI tested empagliflozin prescription immediately after acute myocardial infarction (MI) to reduce hospitalization for heart failure (HF) and mortality. Findings presented at ACC showed that empagliflozin did not significantly reduce the risk of time to first hospitalization for heart failure or all-cause death following acute MI. Furthermore, empagliflozin demonstrated 23% and 33% relative risk reduction of first hospitalization for heart failure and total hospitalization for heart failure, components of the primary and first key secondary endpoints respectively. Butler was also the first author of a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomized trials published last month in The Lancet demonstrating that the GLP-1 receptor agonist semaglutide improved heart failure symptoms and physical limitations in people with obesity-related heart failure with preserved ejection fraction.
Below are more of Butler’s most recent publications. Click image to view.
Progress Notes 
What a great leader and scientist he is and what a tremendous positive mark he left on UMMC. His time spent here at UMMC will never be forgotten. I am so proud to know him and we all know he will continue to be at the top wherever he goes. Congratulations Dr Butler
LikeLike